Ergun et al.34 conducted a meta-analysis which included 636,535 patients and concluded that HER2-low was associated with better DFS and OS compared with HER2-0 in early-stage breast cancer, regardless of HR status. This evidence concerns the gene ERBB2 and breast cancer.